for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

MYOS RENS Technology Inc

MYOS.OQ

Latest Trade

1.50USD

Change

0.00(0.00%)

Volume

8,080

Today's Range

1.50

 - 

1.60

52 Week Range

1.06

 - 

2.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.50
Open
1.60
Volume
8,080
3M AVG Volume
0.28
Today's High
1.60
Today's Low
1.50
52 Week High
2.00
52 Week Low
1.06
Shares Out (MIL)
9.17
Market Cap (MIL)
14.31
Forward P/E
-3.12
Dividend (Yield %)
--

Latest Developments

More

MYOS RENS Technology Qtrly Loss Per Share $0.13

Myos Rens Technology Reports Fourth Quarter Results

MYOS RENS Expects revenues To Increase In 2019

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About MYOS RENS Technology Inc

MYOS RENS Technology Inc. (MYOS), formerly MYOS Corporation, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity. The Company is focused on the discovery, development, and commercialization of nutritional supplements, functional foods, therapeutic products, and other technologies for maintaining the health and performance of muscle tissue. MYOS is evaluating the modulation of myostatin. Its research is focused on developing strategies and therapeutic interventions to address muscle related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases. The Company, through its subsidiary, holds the intellectual property pertaining to Fortetropin, which is a dietary supplement.

Industry

Biotechnology & Drugs

Contact Info

45 Horsehill Rd Ste 106

+1.973.5090444

https://www.myosrens.com/

Executive Leadership

Robert J. Hariri

Independent Chairman of the Board

Joseph Mannello

Chief Executive Officer

Victor E. Mandel

Director

Christopher R. Pechock

Director

Bin Zhou

Director

Key Stats

Revenue (MM, USD)

2018

0.0K

2019(E)

0.0K
EPS (USD)

2018

-0.450

2019(E)

-0.500
Price To Earnings (TTM)
--
Price To Sales (TTM)
27.62
Price To Book (MRQ)
4.40
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
24.12
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-87.42
Return on Equity (TTM)
-72.18

Latest News

BRIEF-Myos Rens Technology Reports Qtrly Loss Per Share $0.19

* MYOS RENS TECHNOLOGY REPORTS FIRST QUARTER FINANCIAL RESULTS

BRIEF-Joseph Mannello Reports 9.3 Pct Stake In Myos Rens Technology Inc

* JOSEPH MANNELLO REPORTS 9.3 PERCENT STAKE IN MYOS RENS TECHNOLOGY INC AS OF APRIL 27, 2018 - SEC FILING Source text: (https://bit.ly/2FTnvnk) Further company coverage:

BRIEF-David Matlin Reports 8.29 Pct Passive Stake In MYOS RENS Technology As Of April 25, 2018

* DAVID J. MATLIN REPORTS 8.29 PERCENT PASSIVE STAKE IN MYOS RENS TECHNOLOGY AS OF APRIL 25, 2018 - SEC FILING Source text : (https://bit.ly/2rgSl4d) Further company coverage:

BRIEF-Myos Rens Says Qtrly Net Loss Rose 44 Pct To $1.1 MLN

* MYOS RENS TECHNOLOGY REPORTS FOURTH QUARTER AND FISCAL 2017 FINANCIAL RESULTS

BRIEF-Myos Rens Technology Announces Research Agreement With Rutgers University

* MYOS RENS TECHNOLOGY, INC. ANNOUNCES RESEARCH AGREEMENT WITH RUTGERS UNIVERSITY FOCUSED ON DISCOVERY OF COMPOUNDS AND PRODUCTS FOR IMPROVING MUSCLE HEALTH AND PERFORMANCE Source text for Eikon: Further company coverage:

BRIEF-Myos Rens Technology CEO Issues Shareholder Letter

* MYOS RENS TECHNOLOGY CEO ISSUES SHAREHOLDER LETTER Source text for Eikon: Further company coverage:

BRIEF-MYOS RENS Technology reports qtrly loss per share $‍0.13​

* MYOS RENS Technology Inc reports third quarter 2017 financial results

BRIEF-Myos Rens Technology files for mixed shelf of up to $75 mln

* Files for mixed shelf of up to $75 million - sec filing Source text: (http://bit.ly/2z7GifH) Further company coverage:

BRIEF-Myos Rens Technology Inc appoints Joseph Mannello as permanent CEO

* Myos Rens Technology Inc appoints Joseph Mannello as permanent chief executive officer

BRIEF-Myos Rens Technology elects Joseph Mannello CEO​

* Myos Rens Technology Inc says on August 24 board elected Joseph Mannello as chief executive officer of company, effective immediately - SEC filing

BRIEF-MYOS RENS TECHNOLOGY ANNOUNCES $2.1 MLN REGISTERED DIRECT OFFERING

* MYOS RENS TECHNOLOGY INC. ANNOUNCES $2,125,000 REGISTERED DIRECT OFFERING

BRIEF-Myos Rens Technology enters into an amended supply agreement with Dil Technologie GMBH

* Myos Rens Technology Inc - On November 18, 2016, entered into an amended supply agreement with Dil Technologie GMBH

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up